Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Schedule of Allocation of Purchase Price (Details)

v3.8.0.1
Acquisitions - Schedule of Allocation of Purchase Price (Details) - USD ($)
Feb. 16, 2018
Nov. 17, 2017
Mar. 31, 2018
Dec. 31, 2017
Fair value of liabilities assumed:        
Goodwill     $ 18,678,495 $ 14,292,282
Avadel        
Business Acquisition [Line Items]        
Inventory $ 2,549,000      
Identifiable Intangible Assets:        
Identifiable Intangible Assets: 16,453,000      
Fair value of liabilities assumed:        
Fair value of debt assumed (15,272,303)      
Fair value of contingent consideration and deferred payments (7,875,165)      
Total identifiable net assets (4,145,468)      
Fair value of consideration transferred 240,745      
Goodwill $ 4,386,213      
TRx        
Business Acquisition [Line Items]        
Cash and cash equivalents   $ 11,068    
Accounts receivable, net   2,872,545    
Inventory   495,777    
Prepaid expenses and other current assets   134,281    
Identifiable Intangible Assets:        
Total assets acquired   21,581,671    
Fair value of liabilities assumed:        
Accounts payable   192,706    
Accrued expenses and other current liabilities   4,850,422    
Deferred tax liability   839,773    
Total liabilities assumed   5,882,901    
Total identifiable net assets   15,698,770    
Fair value of consideration transferred   29,991,052    
Goodwill   14,292,282    
PAI Sales & Marketing Agreement | TRx        
Identifiable Intangible Assets:        
Identifiable Intangible Assets:   2,334,000    
Metafolin | Acquired product marketing rights | TRx        
Identifiable Intangible Assets:        
Identifiable Intangible Assets:   10,465,000    
Millipred | Acquired product marketing rights | TRx        
Identifiable Intangible Assets:        
Identifiable Intangible Assets:   4,714,000    
Ulesfia | Acquired product marketing rights | TRx        
Identifiable Intangible Assets:        
Identifiable Intangible Assets:   $ 555,000